AI-generated summary
The authors report a phase 1/2 randomized double-blind dose-escalation trial of bright light therapy in 38 people with bipolar disorder and nonseasonal depression, comparing morning and midday schedules. Two patients (6%) had a hypomanic switch at 45 minutes, and depressive symptoms and clinical global impression scores improved over time. The authors conclude that light therapy is a viable antidepressant strategy that can be safely started at 45 minutes, with careful monitoring.
- Participants
- 38
- Who or what was studied
- Adults with bipolar I or II disorder experiencing nonseasonal depression, taking mood stabilizers
- Limits stated in the abstract
- The abstract does not describe a control-group comparison of efficacy against a placebo condition beyond a one-week placebo phase, and the trial was designed as a dose-escalation study with a small sample.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on psychiatrist.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Dose, Bright light therapy, Depression, Trial registration, Primary outcome. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.